These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 408654)

  • 1. [The structure of drug costs. A criticism of monocausal explanation (author's transl)].
    Nord D
    MMW Munch Med Wochenschr; 1977 Aug; 119(34):1075-8. PubMed ID: 408654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The costs of cancer screening (author's transl)].
    Neumann G
    Geburtshilfe Frauenheilkd; 1975 Aug; 35(8):615-8. PubMed ID: 1175903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Unspecific diseases of the respiratory organs in the statistics of social health insurance].
    Hörnstein F
    Med Welt; 1969 May; 19():1111-25. PubMed ID: 5795616
    [No Abstract]   [Full Text] [Related]  

  • 4. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problems of cost-analysis of diseases, taking bronchial carcinoma as an example (author's transl)].
    Flamm H; Mathauer H; Kunze M; Kunze MJ
    Offentl Gesundheitswes; 1974 Mar; 36(3):157-62. PubMed ID: 4277099
    [No Abstract]   [Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in drug prescribing under the Public Health Reform Law--a survey of general practitioners' attitudes in East and West Germany.
    Himmel W; Kron M; Thies-Zajonc S; Kochen MM
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):164-9. PubMed ID: 9112138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Social problem associated with drugs].
    Palenzona C
    Minerva Med; 1978 Jan; 69(4):271-4. PubMed ID: 625379
    [No Abstract]   [Full Text] [Related]  

  • 9. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The drug problem in the opinion of working women--representative study].
    Biener K
    Offentl Gesundheitswes; 1981 Nov; 43(11):578-82. PubMed ID: 6212804
    [No Abstract]   [Full Text] [Related]  

  • 12. [The physician and drug costs].
    Kimbel KH
    MMW Munch Med Wochenschr; 1977 Aug; 119(34):1061-2. PubMed ID: 408652
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany.
    Zeidler J; Mittendorf T; Vahldiek G; Zeidler H; Merkesdal S
    Rheumatology (Oxford); 2008 Oct; 47(10):1527-34. PubMed ID: 18682412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of age structure of patients on the amount of expenditures for drugs].
    Zouplna K
    Cesk Zdrav; 1966 Sep; 14(9):498-500. PubMed ID: 5988859
    [No Abstract]   [Full Text] [Related]  

  • 16. The older adult and drug therapy: Part two. Thirteen drugs and what they cost.
    Geriatr Nurs; 1982; 3(1):48-9. PubMed ID: 6916681
    [No Abstract]   [Full Text] [Related]  

  • 17. [Data cross-cut and the field of rehabilitation medicine at a vocational re-training centre (author's transl)].
    Kollmeier H; Wehmeier G
    Rehabilitation (Stuttg); 1977 Feb; 16(1):25-30. PubMed ID: 841167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The development of drug utilization with special reference to demographic factors].
    Mansky T; Erben CM; Reichelt H; Scriba PC
    Offentl Gesundheitswes; 1989 Oct; 51(10):592-8. PubMed ID: 2531309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Some recommendations on the determination of financial responsiblity for the treatment of drug addicts (author's transl)].
    Hölken H
    Rehabilitation (Stuttg); 1973 Aug; 12(3):152-7. PubMed ID: 4787379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.